2023
82P NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies
Choo J, Jeraj S, Chan G, Sundar R, Yong W, Lee M, Ngoi N, Wong A, Soo R, Chee C, Lim J, Goh B, Lee S, Tan D. 82P NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies. Annals Of Oncology 2023, 34: s1498. DOI: 10.1016/j.annonc.2023.10.217.Peer-Reviewed Original Research1550P Evaluating the novel combination of pressurized intraperitoneal aerosol chemotherapy-oxaliplatin (PIPAC-OX) as an immunomodulator in combination with systemic nivolumab for gastric cancer peritoneal metastases
Sundar R, Chia D, Ceelen W, Chia C, Kim G, Shabbir A, Willaert W, Ong J, Wong J, Seo C, Tan H, Callebout E, Geboes K, Ng M, Lum J, Leow W, Selvarajan S, Hoorens A, Yong W, So J. 1550P Evaluating the novel combination of pressurized intraperitoneal aerosol chemotherapy-oxaliplatin (PIPAC-OX) as an immunomodulator in combination with systemic nivolumab for gastric cancer peritoneal metastases. Annals Of Oncology 2023, 34: s869. DOI: 10.1016/j.annonc.2023.09.1462.Peer-Reviewed Original Research
2015
Nivolumab in NSCLC: latest evidence and clinical potential
Sundar R, Cho B, Brahmer J, Soo R. Nivolumab in NSCLC: latest evidence and clinical potential. Therapeutic Advances In Medical Oncology 2015, 7: 85-96. PMID: 25755681, PMCID: PMC4346216, DOI: 10.1177/1758834014567470.Peer-Reviewed Original ResearchNon-small cell lung cancerStudy of nivolumabImmune checkpoint modulatorsPD-1 inhibitorsCell lung cancerMolecular targeted therapyTreatment of patientsEarly phase studiesHost immune responseUnresectable melanomaPD-1Checkpoint modulatorsSolid tumorsNivolumabEvading host immune responsesImmune modulationLung cancerImmune responseClinical potentialImmune systemLigand pathwayRegulatory approvalTumorPatientsChemotherapy